KRTAP10-7

Across TCGA pan-cancer cohorts, KRTAP10-7 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated KRTAP10-7 data layer compared with 13 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher KRTAP10-7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KRTAP10-7 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

SCLC, LUSC, and UCEC are the cancer types where KRTAP10-7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.055	0.708	<.001	36	view →
LUSC	OS	Median	All	0.172	0.762	.002	18	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUAD	OS	Median	II,III,IV	0.168	0.681	.001	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
SKCM	DFS	Median	II,III,IV	1.000	0.667	.018	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

KRTAP10-7–SCLC (OS)

Open the SCLC breakdown →